Home > Publishers > GervanoRA Data Services LLP
  • Japanese
  • Korean
  • Traditional Chinese
  • Simplified Chinese
Publisher
Filter

GervanoRA Data Services LLP Report List

gerv
GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports and consulting services, based in Goa, India. GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends. We continuously strive to be ahead of our competitors by providing unique competitive analytics like pipeline analysis reports, Epidemiology and epidemiology forecasts, clinical trials database based reports, country insights, market and opportunity assessment reports are few among many other offerings at affordable prices. We assure quality with team work and we collaboratively work with a wide range of organizations (KOLs) to garner valuable key insights. Vast & tailor made databases, healthcare specific global coverage, and expertise making us one of the unique consulting service providers in the world.

Filter
Title Search
1 - 25 of 70 Products Sort by Display
Transient Ischemic Attack - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
Published by
GervanoRA Data Services LLP
Product code
1069396
Published
April 1, 2022
Content info
142 Pages
Price
USD 7000
Sample available
Hemorrhagic Stroke - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
Published by
GervanoRA Data Services LLP
Product code
1069395
Published
March 21, 2022
Content info
186 Pages
Price
USD 7000
Sample available
Ischemic Stroke - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
Published by
GervanoRA Data Services LLP
Product code
1069394
Published
March 11, 2022
Content info
225 Pages
Price
USD 7000
Sample available
Stroke - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
Published by
GervanoRA Data Services LLP
Product code
1069393
Published
February 19, 2022
Content info
391 Pages
Price
USD 11000
Sample available
Moderate to Severe TBIs - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
Published by
GervanoRA Data Services LLP
Product code
1069392
Published
January 25, 2022
Content info
175 Pages
Price
USD 7000
Sample available
Concussion - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
Published by
GervanoRA Data Services LLP
Product code
1069391
Published
January 15, 2022
Content info
150 Pages
Price
USD 7000
Sample available
Kaposi's Sarcoma - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
Published by
GervanoRA Data Services LLP
Product code
1069390
Published
December 29, 2021
Content info
128 Pages
Price
USD 7000
Sample available
Actinic Keratosis - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
Published by
GervanoRA Data Services LLP
Product code
1069389
Published
December 24, 2021
Content info
132 Pages
Price
USD 7000
Sample available
Cutaneous T-Cell Lymphoma - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
Published by
GervanoRA Data Services LLP
Product code
1069388
Published
December 20, 2021
Content info
151 Pages
Price
USD 7000
Sample available
Merkel Cell Carcinoma - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
Published by
GervanoRA Data Services LLP
Product code
1069387
Published
December 11, 2021
Content info
146 Pages
Price
USD 7000
Sample available
Squamous Cell Carcinoma - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
Published by
GervanoRA Data Services LLP
Product code
1069386
Published
December 6, 2021
Content info
155 Pages
Price
USD 7000
Sample available
Basal Cell Carcinoma - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
Published by
GervanoRA Data Services LLP
Product code
1069385
Published
November 30, 2021
Content info
170 Pages
Price
USD 7000
Sample available
Non-Melanoma Skin Cancers - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
Published by
GervanoRA Data Services LLP
Product code
1069384
Published
November 25, 2021
Content info
215 Pages
Price
USD 11000
Sample available
Melanoma - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report
Published by
GervanoRA Data Services LLP
Product code
1069383
Published
November 16, 2021
Content info
273 Pages
Price
USD 7000
Sample available
Seborrheic Dermatitis - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
Published by
GervanoRA Data Services LLP
Product code
1035550
Published
November 6, 2021
Content info
210 Pages
Price
USD 7000
Sample available
Nevoid Basal Cell Carcinoma Syndrome - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
Published by
GervanoRA Data Services LLP
Product code
1035549
Published
November 2, 2021
Content info
175 Pages
Price
USD 7000
Sample available
Angelman Syndrome - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
Published by
GervanoRA Data Services LLP
Product code
1035548
Published
October 29, 2021
Content info
205 Pages
Price
USD 7000
Sample available
Non-Alcoholic Steatohepatitis - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
Published by
GervanoRA Data Services LLP
Product code
1035547
Published
October 26, 2021
Content info
180 Pages
Price
USD 7000
Sample available
Systemic Scleroderma (Sclerosis) - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
Published by
GervanoRA Data Services LLP
Product code
1035546
Published
October 22, 2021
Content info
155 Pages
Price
USD 7000
Sample available
Primary Hyperoxaluria Type 1 - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
Published by
GervanoRA Data Services LLP
Product code
1035545
Published
October 19, 2021
Content info
170 Pages
Price
USD 7000
Sample available
Rett Syndrome - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
Published by
GervanoRA Data Services LLP
Product code
1035544
Published
October 15, 2021
Content info
130 Pages
Price
USD 7000
Sample available
Chimeric Antigen Receptor (CAR) T-Cell Therapy - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
Published by
GervanoRA Data Services LLP
Product code
1035543
Published
October 12, 2021
Content info
325 Pages
Price
USD 11000
Sample available
Traumatic Brain Injury - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
Published by
GervanoRA Data Services LLP
Product code
1035542
Published
October 8, 2021
Content info
275 Pages
Price
USD 7000
Sample available
Erythromelalgia - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
Published by
GervanoRA Data Services LLP
Product code
1035541
Published
October 5, 2021
Content info
132 Pages
Price
USD 7000
Sample available
Acute Myeloid Leukemia - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis
Published by
GervanoRA Data Services LLP
Product code
1024215
Published
August 16, 2021
Content info
250 Pages
Price
USD 7000
Sample available
Compare
item is currently selected
Compare products
Delete all